Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies

• Alliance to initially focus on four checkpoint modulator programs directed at GITR, OX40, TIM-3 and LAG-3

• Incyte to have access to Agenus’ proprietary Retrocyte Display™ platform for the discovery of additional therapeutic antibodies

• Agenus to receive $60 million comprised of a $25 million technology and program access fee under the collaboration plus $35 million equity investment in Agenus at $4.51/share

• Agenus eligible to receive up to $350 million in development, regulatory and commercial milestones across the four lead programs

WILMINGTON, Del. & LEXINGTON, Mass.-- Incyte Corporation (INCY) and Agenus Inc. (AGEN) today announced a global license, development and commercialization agreement focused on novel immuno-therapeutics using Agenus’ proprietary Retrocyte Display™ antibody discovery platform.

BIND Therapeutics Provides Clinical Update for BIND-014 and 2015 Strategic Overview

– Enrolled first NSCLC patient with KRAS mutation in phase 2 KRAS mutant or squamous histology NSCLC trial based on encouraging clinical activity from ongoing phase 2 trial with goal of rapid advancement to pivotal studies – – Initiating Phase 2 clinical trials in a broader array of tumors with a rationale for BIND-014 activity, including cholangiocarcinoma, cervical cancer, bladder cancer and head and neck cancer – – Reported topline clinical activity and safety data for BIND-014 in mCRPC, providing further validation for the differentiated Accurin platform – – Achieved development milestone as part of the Pfizer collaboration –

CAMBRIDGE, Mass.-- BIND Therapeutics, Inc. (BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced its 2015 strategic overview and enrollment of the first patient expressing a KRAS mutation in a global, multicenter two-tiered phase 2 trial with BIND-014 in non-small cell lung cancer (NSCLC) patients with KRAS mutant tumors (mutated Kirsten ras oncogene homolog) or squamous histology.

Arena Pharmaceuticals Reports Positive Results from Phase 1b Clinical Trial Evaluating APD334 for the Treatment of Autoimmune Diseases

- Trial results show novel S1P1 modulator produced strong, dose-dependent lymphocyte lowering -
- No clinically significant safety findings relative to heart, liver or pulmonary function -

SAN DIEGO, Jan. 7, 2015 -- Arena Pharmaceuticals, Inc. (ARNA) today announced top-line results from a Phase 1b multiple ascending dose clinical trial for APD334, an oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P₁) receptor for the potential treatment of autoimmune diseases.

In the Phase 1b clinical trial, APD334 demonstrated a dose-dependent effect on lymphocyte count lowering in blood, with mean decreases from baseline of up to 69%. Lymphocyte counts, on average, recovered to baseline within one week of conclusion of dosing.